256 related articles for article (PubMed ID: 25293656)
21. Significant association of serum autoantibodies to TYMS, HAPLN1 and IGFBP5 with early stage canine malignant mammary tumours.
Chang SC; Yuan SH; Li CY; Chang HM; Wang HC; Pan YA; Hsueh PC; Wu CC; Yang Y; Liu HP
Vet Comp Oncol; 2021 Mar; 19(1):172-182. PubMed ID: 33038064
[TBL] [Abstract][Full Text] [Related]
22. Significance of caveolin-1 and matrix metalloproteinase 14 gene expression in canine mammary tumours.
Ebisawa M; Iwano H; Nishikawa M; Tochigi Y; Komatsu T; Endou Y; Hirayama K; Taniyama H; Kadosawa T; Yokota H
Vet J; 2015 Nov; 206(2):191-6. PubMed ID: 26364240
[TBL] [Abstract][Full Text] [Related]
23. Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.
Selting KA; Ringold R; Husbands B; Pithua PO
J Vet Intern Med; 2016 Jul; 30(4):1159-66. PubMed ID: 27214230
[TBL] [Abstract][Full Text] [Related]
24. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
25. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.
von Euler H; Eriksson S
Vet Comp Oncol; 2011 Mar; 9(1):1-15. PubMed ID: 21303450
[TBL] [Abstract][Full Text] [Related]
26. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
Jagarlamudi KK; Shaw M
Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
[TBL] [Abstract][Full Text] [Related]
27. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.
Pan ZL; Ji XY; Shi YM; Zhou J; He E; Skog S
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1193-9. PubMed ID: 20140744
[TBL] [Abstract][Full Text] [Related]
28. Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.
Wang L; Sharif H; Saellström S; Rönnberg H; Eriksson S
BMC Vet Res; 2021 Sep; 17(1):316. PubMed ID: 34579716
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma.
Wang L; Unger L; Sharif H; Eriksson S; Gerber V; Rönnberg H
BMC Mol Cell Biol; 2021 Dec; 22(1):59. PubMed ID: 34906077
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of expression of the Wnt signaling components in canine mammary tumors via RT
Yu F; Rasotto R; Zhang H; Pei S; Zhou B; Yang X; Jin Y; Zhang D; Lin D
J Vet Sci; 2017 Sep; 18(3):359-367. PubMed ID: 27586466
[TBL] [Abstract][Full Text] [Related]
31. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
32. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer.
Larsson AM; Bendahl PO; Aaltonen K; Jansson S; Forsare C; Bergqvist M; Jørgensen CLT; Rydén L
Sci Rep; 2020 Mar; 10(1):4484. PubMed ID: 32161278
[TBL] [Abstract][Full Text] [Related]
33. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
34. Advancing canine mammary tumor diagnostics: Unraveling the diagnostic potential of Cytokeratin 19 through droplet digital PCR analysis.
Tanvetthayanont P; Yata T; Boonnil J; Temisak S; Ponglowhapan S
Theriogenology; 2024 Mar; 217():127-135. PubMed ID: 38271766
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.
Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S
Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220
[TBL] [Abstract][Full Text] [Related]
36. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
[TBL] [Abstract][Full Text] [Related]
37. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
Li Z; Wang Y; He J; Ma J; Zhao L; Chen H; Li N; Zhou J; He E; Skog S
Eur J Cancer Prev; 2010 Jul; 19(4):313-8. PubMed ID: 20479645
[TBL] [Abstract][Full Text] [Related]
38. Human thymidine kinase 1. Regulation in normal and malignant cells.
Munch-Petersen B; Cloos L; Jensen HK; Tyrsted G
Adv Enzyme Regul; 1995; 35():69-89. PubMed ID: 7572355
[TBL] [Abstract][Full Text] [Related]
39. Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease.
Selting KA; Sharp CR; Ringold R; Knouse J
Vet Comp Oncol; 2015 Dec; 13(4):373-84. PubMed ID: 23859156
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of the KLF4 transcription factor inhibits the proliferation and migration of canine mammary tumor cells.
Tien YT; Chang MH; Chu PY; Lin CS; Liu CH; Liao AT
Vet J; 2015 Aug; 205(2):244-53. PubMed ID: 25616642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
